US8975392B2 - Methods for isolating crystalline form I of 5-azacytidine - Google Patents
Methods for isolating crystalline form I of 5-azacytidine Download PDFInfo
- Publication number
- US8975392B2 US8975392B2 US13/913,163 US201313913163A US8975392B2 US 8975392 B2 US8975392 B2 US 8975392B2 US 201313913163 A US201313913163 A US 201313913163A US 8975392 B2 US8975392 B2 US 8975392B2
- Authority
- US
- United States
- Prior art keywords
- solvent
- azacytidine
- acetate
- polar solvent
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NMUSYJAQQFHJEW-ZPQYLTHOSA-N [H]C1(O)[C@]([H])(O)[C@]([H])(N2C=NC(N)=NC2=O)O[C@]1([H])CO Chemical compound [H]C1(O)[C@]([H])(O)[C@]([H])(N2C=NC(N)=NC2=O)O[C@]1([H])CO NMUSYJAQQFHJEW-ZPQYLTHOSA-N 0.000 description 2
- GTGFZVKCTLEGCA-WDPWISTFSA-N CC[Si](=O)CC1=NC=NC(N[Si](C)(C)C)=N1.CC[Si](=O)CC1=NC=NC(N[Si](C)(C)C)=N1.C[Si](C)(C)N[Si](C)(C)C.NC1=NC(O)=NC=N1.[H]C1(O)[C@]([H])(O)[C@]([H])(N2C=NC(N)=NC2=O)O[C@]1([H])CO.[H]C1(OC(C)=O)[C@]([H])(OC(C)=O)[C@]([H])(OC(C)=O)O[C@]1([H])CC Chemical compound CC[Si](=O)CC1=NC=NC(N[Si](C)(C)C)=N1.CC[Si](=O)CC1=NC=NC(N[Si](C)(C)C)=N1.C[Si](C)(C)N[Si](C)(C)C.NC1=NC(O)=NC=N1.[H]C1(O)[C@]([H])(O)[C@]([H])(N2C=NC(N)=NC2=O)O[C@]1([H])CO.[H]C1(OC(C)=O)[C@]([H])(OC(C)=O)[C@]([H])(OC(C)=O)O[C@]1([H])CC GTGFZVKCTLEGCA-WDPWISTFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Definitions
- the invention relates to the isolation of crystalline polymorphic Form I of 5-azacytidine (also known as azacitidine and 4-amino-1- ⁇ -D-ribofuranosyl-S-triazin-2(1H)-one).
- 5-azacytidine may be used in the treatment of disease, including the treatment of myelodysplastic syndromes (MDS).
- Polymorphs exist as two or more crystalline phases that have different arrangements and/or different conformations of the molecule in a crystal lattice.
- a solvent molecule(s) is contained within the crystal lattice the resulting crystal is called a pseudopolymorph, or solvate.
- the solvent molecule(s) within the crystal structure is a water molecule, then the pseudopolymorph/solvate is called a hydrate.
- the polymorphic and pseudopolymorphic solids display different physical properties, including those due to packing, and various thermodynamic, spectroscopic, interfacial and mechanical properties (See H. Brittain, Polymorphism in Pharmaceutical Solids, Marcel Dekker, New York, N.Y., 1999, pp. 1-2).
- Polymorphic and pseudopolymorphic forms of the drug substance also known as the “active pharmaceutical ingredient” (API)
- API active pharmaceutical ingredient
- a drug product also known as the final or finished dosage form, or as the pharmaceutical composition
- API active pharmaceutical ingredient
- Polymorphic and pseudopolymorphic forms of the drug substance are well known and may affect, for example, the solubility, stability, flowability, fractability, and compressibility of drug substances and the safety and efficacy of drug products, (see, e.g., Knapman, K Modem Drug Discoveries, Mar. 2000: 53).
- 5-azacytidine also known as azacitidine and 4-amino-1- ⁇ -D-ribofuranosyl-S-triazin-2(1H)-one; National Service Center designation NSC-102816; CAS Registry Number 320-67-2) has undergone NCI-sponsored trials for the treatment of myelodysplastic syndromes (MDS). See Komblith et al., J. Clin. Oncol. 20(10): 2441-2452 (2002) and Silverman et al., J. Clin. Oncol. 20(10): 2429-2440 (2002).
- 5-azacytidine may be defined as having a formula of C 8 H 12 N 4 O 5 , a molecular weight of 244.20 and a structure of:
- Forms of 5-azacytidine In the United States patent application entitled “Forms of 5-azacytidine,” filed Mar. 17, 2003 and incorporated herein by reference in its entirety, eight different polymorphic and pseudopolymorphic forms of 5-azacytidine (Forms I-VIII), in addition to an amorphous form, are described. Forms each have characteristic X-Ray Powder Diffraction (XRPD) patterns and are easily distinguished from one another using XRPD.
- XRPD X-Ray Powder Diffraction
- 5-azacytidine drug substance used in the previous clinical trials has typically been synthesized from 5-azacytosine and 1,2,3,5,-tetra-O-acetyl- ⁇ -D-ribofuranose by the method presented in Example 1.
- the last step of this method is a recrystallization of the crude synthesis product from a methanol/DMSO co-solvent system. Specifically, the crude synthesis product is dissolved in DMSO (preheated to about 90° C.), and then methanol is added to the DMSO solution. The product is collected by vacuum filtration and allowed to air dry.
- the present invention provides methods for robustly and reproducibly isolating 5-azacytidine as polymorphic Form I substantially free of other forms.
- the methods involve recrystallizing dissolved 5-azacytidine from a primary solvent/co-solvent mixture and then collecting the resultant crystals.
- the invention also provides pharmaceutical compositions comprising Form I of 5-azacytidine together with a pharmaceutically acceptable excipient, diluent, or carrier.
- Form I of 5-azacytidine may be reproducibly isolated substantially free of other forms by recrystallizing dissolved 5-azacytidine and collecting the resultant crystals.
- 5-azacytidine is first dissolved completely in at least one suitable primary solvent, preferably a polar solvent, more preferably a polar aprotic solvent.
- suitable polar aprotic solvents include, but are not limited to, dimethylformamide (DMF), dimethylacetamide (DMA), dimethylsulfoxide (DMSO), and N-methylpyrrolidinone (NMP).
- the most preferred polar aprotic solvent is DMSO.
- Mixtures of two or more primary solvents are also contemplated for dissolving the 5-azacytidine, for example a mixture of DMSO and DMF.
- the 5-azacytidine used to form the solution may be synthesized by any procedure known in the art; an exemplary prior art synthesis scheme is provided in Example 1. Any polymorphic or pseudopolymorphic form(s) of 5-azacytidine, including mixed phases, may be used to form the solution. Amorphous 5-azacytidine may also be used to form the solution. It is preferred, but not required, that the primary solvent is preheated to an elevated temperature in order to ensure that the 5-azacytidine is dissolved completely.
- An especially preferred primary solvent is dimethyl sulfoxide, (DMSO), most preferably preheated to a temperature in the range of about 40° C. to about 90° C.
- co-solvents include C 2 -C 5 alcohols (which term hereinafter refers to C 2 -C 5 alcohols that are independently: branched or unbranched, substituted or unsubstituted), aliphatic ketones (which term hereinafter refers to aliphatic ketones that are indepedently: branched or unbranched, substituted or unsubstituted), and alkyl cyanides (which term hereinafter refers to alkyl cyanides that are independently: branched or unbranched, substituted or unsubstituted).
- C 2 -C 5 alcohols aliphatic ketones, and alkyl cyanides, along with other suitable solvents, are listed below as Class 2 (solvents to be limited) and Class 3 (solvents of low toxic potential) per the International Conference on Harmonization's (ICH) Guideline for Residual Solvents, July 1997).
- Class 2 solvents to be limited
- Class 3 solvents of low toxic potential
- co-solvents are preheated before mixing with the primary solvent, preferably to a temperature below the temperature at which a substantial portion of the co-solvent would boil, most preferably to about 50° C. It is also preferred, but not required, that the co-solvent(s) is added gradually to the primary solvent(s).
- the primary solvent(s)/co-solvent(s) mixture is then equilibrated at different temperatures in order to promote either a slow recrystallization or a fast recrystallization of Form I of 5-azacytidine, as described below.
- slow recrystallization is meant that the co-solvent/DMSO solution is allowed to equilibrate at a temperature in the range from about 0° C. to about 40° C., preferably in the range of about 15° C. to about 30° C., and most preferably at about ambient temperature.
- Slow recrystallization of Form I of 5-azacytidine is preferably performed using C 2 -C 5 alcohols, aliphatic ketones, or alkyl cyanides as the co-solvent. More preferably, slow recrystallization is performed with Class 3 C 2 -C 5 alcohols, Class 3 aliphatic ketones, or acetonitrile (Class 2).
- the most preferred Class 3 C 2 -C 5 alcohols are ethanol, isopropyl alcohol, and 1-propanol, and the most preferred Class 3 aliphatic ketone is methylethyl ketone.
- fast recrystallization is meant that the co-solvent solution is allowed to equilibrate at a temperature of below 0° C., preferably below about ⁇ 10° C., and most preferably at about ⁇ 20° C.
- Fast recrystallization of Form I of 5-azacytidine is preferably performed with a C 3 -C 5 alcohol (which term hereinafter refers to C 3 -C 5 alcohols which are independently: branched or unbranched, substituted or unsubstituted) or an alkyl cyanide as the co-solvent. More preferably the C 3 -C 5 alcohol is a Class 3 solvent, and the alkyl cyanide is acetonitrile. The most preferred Class 3 C 3 -C 5 alcohols are isopropyl alcohol (2-propanol) and 1-propanol.
- Non-limiting examples of protocols for the recrystallization of Form I according to the methods described herein are provided in Examples 2 (slow recrystallization with DMSO as the primary solvent and ethanol, isopropyl alcohol, acetonitrile, or methylethyl ketone as the co-solvent) and 3 (fast recrystallization with DMSO as the primary solvent, and isopropyl alcohol or acetonitrile as the co-solvent) below.
- the Form I of 5-azacytidine crystals may be isolated from the co-solvent mixture by any suitable method known in the art.
- the Form I crystals are isolated using vacuum filtration through a suitable filter medium or by centrifugation.
- Form I of 5-azacytidine as the drug substance reproducibly and robustly.
- isopropyl alcohol and acetonitrile reliably produce Form I independent of cooling rate (either slow recrystallization or fast recrystallization) and are preferred as the recrystallization co-solvents to recover Form I.
- Form I is isolated using isopropyl alcohol as the co-solvent since isopropyl alcohol carries a Class 3 risk classification (solvent of low toxic potential), whereas acetonitrile carries a Class 2 risk classification (solvent to be limited).
- Form I of 5-azacytidine may be reliably recovered for the first time from solvents of low toxic potential without requiring control over the rate of recrystallation.
- Form I of 5-azacytidine may be recovered simply by dissolving 5-azacytidine in DMSO (preferably heated to a temperature in the range of about 40° C. to about 90° C. prior to the addition of 5-azacytidine), adding isopropyl alcohol, and allowing the resulting solvent mixture to equilibrate at about ambient temperature.
- Form I of 5-azacytidine may be recovered from a primary solvent(s)/co-solvent(s) mixture by “seeding” with a small amount of Form I of 5-azacytidine either prior to, or during, the addition of the co-solvent(s).
- seeding with Form I, it is possible to expand the list of suitable co-solvents and co-solvent classes beyond those listed above. For example, it is known that recrystallization from the DMSO/methanol system produces either Form I, or a Form VII mixed phase (see Example 1).
- Form I of 5-azacytidine may be reliably isolated.
- the present invention allows for the first time the production of 5-azacytidine drug substance with uniform and consistent properties from batch to batch, which properties include but are not limited to solubility and dissolution rate. In turn, this allows one to provide 5-azacytidine drug product (see below) which also has uniform and consistent properties from batch to batch.
- a pharmaceutical formulation also known as the “drug product” or “pharmaceutical composition” preferably in unit dose form, comprising one or more of the 5-azacytidine polymorphs of the present invention and one or more pharmaceutically acceptable carrier, diluent, or excipient.
- a pharmaceutical formulation also known as the “drug product” or “pharmaceutical composition”
- pharmaceutically acceptable carrier diluent, or excipient.
- Form I 5-azacytidine prepared according to the methods provided herein is used to prepare the pharmaceutical formulation.
- Such pharmaceutical formulation may, without being limited by the teachings set forth herein, include a solid form of the present invention which is blended with at least one pharmaceutically acceptable excipient, diluted by an excipient or enclosed within such a carrier that can be in the form of a capsule, sachet, tablet, buccal, lozenge, paper, or other container.
- a pharmaceutically acceptable excipient diluted by an excipient or enclosed within such a carrier that can be in the form of a capsule, sachet, tablet, buccal, lozenge, paper, or other container.
- the excipient serves as a diluent, it may be a solid, semi-solid, or liquid material which acts as a vehicle, carrier, or medium for the 5-azacytidine polymorph(s).
- the formulations can be in the form of tablets, pills, powders, elixirs, suspensions, emulsions, solutions, syrups, capsules (such as, for example, soft and hard gelatin capsules), suppositories, sterile injectable solutions, and sterile packaged powders.
- excipients include, but are not limited to, starches, gum arabic, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
- the formulations can additionally include lubricating agents such as, for example, talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propyl-hydroxybenzoates; sweetening agents; or flavoring agents.
- lubricating agents such as, for example, talc, magnesium stearate and mineral oil
- wetting agents such as talc, magnesium stearate and mineral oil
- emulsifying and suspending agents such as methyl- and propyl-hydroxybenzoates
- sweetening agents or flavoring agents.
- Polyols, buffers, and inert fillers may also be used.
- polyols examples include, but are not limited to: mannitol, sorbitol, xylitol, sucrose, maltose, glucose, lactose, dextrose, and the like.
- Suitable buffers encompass, but are not limited to, phosphate, citrate, tartrate, succinate, and the like.
- Other inert fillers which may be used encompass those which are known in the art and are useful in the manufacture of various dosage forms.
- the solid pharmaceutical compositions may include other components such as bulling agents and/or granulating agents, and the like.
- the compositions of the invention can be formulated so as to provide quick, sustained, controlled, or delayed release of the drug substance after administration to the patient by employing procedures well known in the art.
- the 5-azacytidine polymorph(s) may made into the form of dosage units for oral administration.
- the 5-azacytidine polymorph(s) may be mixed with a solid, pulverant carrier such as, for example, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives or gelatin, as well as with an antifriction agent such as for example, magnesium stearate, calcium stearate, and polyethylene glycol waxes.
- a solid, pulverant carrier such as, for example, lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose derivatives or gelatin
- an antifriction agent such as for example, magnesium stearate, calcium stearate, and polyethylene glycol waxes.
- coated tablets, capsules, or pulvules may be coated with a concentrated solution of sugar, which may contain gum arabic, gelatin, talc, titanium dioxide, or with a lacquer dissolved in the volatile organic solvent or mixture of solvents.
- a concentrated solution of sugar which may contain gum arabic, gelatin, talc, titanium dioxide, or with a lacquer dissolved in the volatile organic solvent or mixture of solvents.
- various dyes may be added in order to distinguish among tablets with different active compounds or with different amounts of the active compound present.
- Soft gelatin capsules may be prepared in which capsules contain a mixture of the 5-azacytidine polymorph(s) and vegetable oil or non-aqueous, water miscible materials such as, for example, polyethylene glycol and the like.
- Hard gelatin capsules may contain granules or powder of the 5-azacytidine polymorph in combination with a solid, pulverulent carrier, such as, for example, lactose, saccharose, sorbitol, mannitol, potato starch, corn starch, amylopectin, cellulose derivatives, or gelatin.
- Tablets for oral use are typically prepared in the following manner, although other techniques may be employed.
- the solid substances are gently ground or sieved to a desired particle size, and a binding agent is homogenized and suspended in a suitable solvent.
- the 5-azacytidine polymorph(s) and auxiliary agents are mixed with the binding agent solution.
- the resulting mixture is moistened to form a uniform suspension.
- the moistening typically causes the particles to aggregate slightly, and the resulting mass is gently pressed through a stainless steel sieve having a desired size.
- the layers of the mixture are then dried in controlled drying units for a pre-determined length of time to achieve a desired particle size and consistency.
- the granules of the dried mixture are gently sieved to remove any powder.
- disintegrating, anti-friction, and anti-adhesive agents are added.
- the mixture is pressed into tablets using a machine with the appropriate punches and dies to obtain the desired tablet size.
- such a formulation typically comprises sterile, aqueous and non-aqueous injection solutions comprising one or more 5-azacytidine polymorphs for which preparations are preferably isotonic with the blood of the intended recipient.
- preparations may contain anti-oxidants, buffers, bacteriostats, and solute; which render the formulation isotonic with the blood of the intended recipient.
- Aqueous and non-aqueous suspensions may include suspending agents and thickening agents.
- the formulations may be present in unit-dose or multi-dose containers, for example, sealed ampules and vials.
- Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the kind previously described.
- Liquid preparations for oral administration are prepared in the form of solutions, syrups, or suspensions with the latter two forms containing, for example, 5-azacytidine polymorph(s), sugar, and a mixture of ethanol, water, glycerol, and propylene glycol. If desired, such liquid preparations contain coloring agents, flavoring agents, and saccharin. Thickening agents such as carboxymethylcellulose may also be used.
- the pharmaceutical formulations of the present invention are preferably prepared in a unit dosage form, each dosage unit containing from about 5 mg to about 200 mg, more usually about 100 mg of the 5-azacytidine polymorph(s).
- dosage unit contains from about 5 to about 200 mg, more usually about 100 mg of the 5-azacytidine polymorph(s).
- unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects/patients or other mammals, each unit containing a predetermined quantity of the 5-azacytidine polymorph calculated to produce the desired therapeutic effect, in association with preferably, at least one pharmaceutically acceptable carrier, diluent, or excipient.
- 5-azacytidine may be synthesized using commercially available 5-azacytosine and 1,2,3,5-tetra-O-acetyl- ⁇ -D-ribofuranose (RTA) according to the following pathway:
- the crude synthesis product is dissolved in DMSO (preheated to about 90° C.), and then methanol is added to the DMSO solution.
- the co-solvent mixture is equilibrated at approximately ⁇ 20° C. to allow 5-azacytidine crystal formation.
- the product is collected by vacuum filtration and allowed to air dry.
- DMSO dimethyl sulfoxide
- 5-azacytidine was dissolved with approximately 5 mL of DMSO, preheated to approximately 90° C., in separate 100-ml beakers. The solids were allowed to dissolve to a clear solution. Approximately 45 mL of isopropyl alcohol or acetonitrile co-solvent, preheated to approximately 50° C., was added to the solution and the resultant solution was mixed. The solution was covered and placed in a freezer to equilibrate at approximately ⁇ 20° C. to allow crystal formation. Solutions were removed from the freezer after crystal formation. The product was collected by vacuum filtration using a Buchner funnel.
- X-ray powder diffraction (XRPD) patterns for each sample were obtained on a Scintag XDS 2000 or a Scintag X 2 ⁇ / ⁇ diffractometer operating with copper radiation at 45 kV and 40 mA using a Kevex Psi Peltier-cooled silicon detector or a Thermo ARL Peltier-cooled solid state detector. Source slits of 2 or 4 mm and detector slits of 0.5 or 0.3 mm were used for data collection. Recrystallized material was gently milled for approximately one minute using an agate mortar and pestle. Samples were placed in a stainless steel or silicon sample holder and leveled using a glass microscope slide. Powder diffraction patterns of the samples were obtained from 2 to 42° 2 ⁇ at 1°/minute. Calibration of the X 2 diffractometer is verified annually using a silicon powder standard.
- XRPD performed according to this method revealed that the Form I of 5-azacytidine was isolated in Example 2 by slow recrystallization using either ethanol, isopropyl alcohol, acetonitrile, or methyl ethyl ketone as the co-solvent, and in Example 3 by fast recrystallization using isopropyl alcohol or acetonitrile as the co-solvent.
- the results indicate that Form I of 5-azacytidine may be reliably recovered from the DMSO/isopropyl alcohol and DMSO/acetonitrile solvent systems without control of the rate of recrystallization.
Abstract
Description
TABLE 1 |
5-azacytidine Form I - the most prominent 2θ angles, d-spacing and |
relative intensities (Cu Kα radiation) |
2θ Angle (°) | d-spacing (Å) | Relative Intensity |
12.182 | 7.260 | 39.1 |
13.024 | 6.792 | 44.1 |
14.399 | 6.146 | 31.5 |
16.470 | 5.378 | 27.1 |
18.627 | 4.760 | 16.0 |
19.049 | 4.655 | 35.9 |
20.182 | 4.396 | 37.0 |
21.329 | 4.162 | 12.4 |
23.033 | 3.858 | 100.0 |
23.872 | 3.724 | 28.0 |
26.863 | 3.316 | 10.8 |
27.135 | 3.284 | 51.5 |
29.277 | 3.048 | 25.6 |
29.591 | 3.016 | 11.5 |
30.369 | 2.941 | 10.8 |
32.072 | 2.788 | 13.4 |
Isolation of Polymorphic Form I of 5-azacytidine by Recrystallization
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/913,163 US8975392B2 (en) | 2003-03-17 | 2013-06-07 | Methods for isolating crystalline form I of 5-azacytidine |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/390,530 US6943249B2 (en) | 2003-03-17 | 2003-03-17 | Methods for isolating crystalline Form I of 5-azacytidine |
US11/198,550 US7700770B2 (en) | 2003-03-17 | 2005-08-05 | Methods for isolating crystalline form I of 5-azacytidine |
US12/729,116 US8211862B2 (en) | 2003-03-17 | 2010-03-22 | Pharmaceutical compositions comprising crystal forms of 5-azacytidine |
US13/489,307 US8481715B2 (en) | 2003-03-17 | 2012-06-05 | Methods for isolating crystalline form I of 5-azacytidine |
US13/913,163 US8975392B2 (en) | 2003-03-17 | 2013-06-07 | Methods for isolating crystalline form I of 5-azacytidine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/489,307 Division US8481715B2 (en) | 2003-03-17 | 2012-06-05 | Methods for isolating crystalline form I of 5-azacytidine |
Publications (2)
Publication Number | Publication Date |
---|---|
US20130274459A1 US20130274459A1 (en) | 2013-10-17 |
US8975392B2 true US8975392B2 (en) | 2015-03-10 |
Family
ID=32987551
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/390,530 Expired - Lifetime US6943249B2 (en) | 2003-03-17 | 2003-03-17 | Methods for isolating crystalline Form I of 5-azacytidine |
US11/198,550 Expired - Lifetime US7700770B2 (en) | 2003-03-17 | 2005-08-05 | Methods for isolating crystalline form I of 5-azacytidine |
US12/729,116 Expired - Lifetime US8211862B2 (en) | 2003-03-17 | 2010-03-22 | Pharmaceutical compositions comprising crystal forms of 5-azacytidine |
US13/489,307 Expired - Lifetime US8481715B2 (en) | 2003-03-17 | 2012-06-05 | Methods for isolating crystalline form I of 5-azacytidine |
US13/913,163 Expired - Lifetime US8975392B2 (en) | 2003-03-17 | 2013-06-07 | Methods for isolating crystalline form I of 5-azacytidine |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/390,530 Expired - Lifetime US6943249B2 (en) | 2003-03-17 | 2003-03-17 | Methods for isolating crystalline Form I of 5-azacytidine |
US11/198,550 Expired - Lifetime US7700770B2 (en) | 2003-03-17 | 2005-08-05 | Methods for isolating crystalline form I of 5-azacytidine |
US12/729,116 Expired - Lifetime US8211862B2 (en) | 2003-03-17 | 2010-03-22 | Pharmaceutical compositions comprising crystal forms of 5-azacytidine |
US13/489,307 Expired - Lifetime US8481715B2 (en) | 2003-03-17 | 2012-06-05 | Methods for isolating crystalline form I of 5-azacytidine |
Country Status (16)
Country | Link |
---|---|
US (5) | US6943249B2 (en) |
EP (3) | EP2181988B1 (en) |
JP (1) | JP4792550B2 (en) |
AU (2) | AU2004222274B2 (en) |
BR (1) | BRPI0408506A (en) |
CA (1) | CA2518973A1 (en) |
CY (2) | CY1114213T1 (en) |
DK (2) | DK1608634T3 (en) |
EC (1) | ECSP056023A (en) |
ES (2) | ES2575535T3 (en) |
HU (1) | HUE028268T2 (en) |
MX (1) | MXPA05009969A (en) |
PL (2) | PL2181988T3 (en) |
PT (2) | PT2181988E (en) |
SI (2) | SI1608634T1 (en) |
WO (1) | WO2004082822A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8902490A (en) * | 1989-10-06 | 1991-05-01 | Leonardus Mathijs Marie Nevels | METHOD FOR CLEANING FLUE GASES |
ATE314768T1 (en) * | 2001-10-08 | 2006-01-15 | Cit Alcatel | METHOD FOR DISTRIBUTING LOAD BETWEEN SEVERAL COMMON EQUIPMENT IN A COMMUNICATIONS NETWORK AND NETWORK FOR APPLYING THE METHOD |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7038038B2 (en) * | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
US6943249B2 (en) * | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
US6887855B2 (en) * | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
US7192781B2 (en) * | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008088779A2 (en) * | 2007-01-11 | 2008-07-24 | Ivax Pharmaceuticals S.R.O. | Solid state forms of 5-azacytidine and processes for preparation thereof |
WO2009016617A2 (en) * | 2007-08-02 | 2009-02-05 | Chemagis Ltd. | Stable highly pure azacitidine and preparation methods therefor |
KR20100102092A (en) * | 2007-09-26 | 2010-09-20 | 마운트 시나이 스쿨 오브 메디신 | Azacytidine analogues and uses thereof |
CA2742252A1 (en) * | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
BRPI0912717A2 (en) | 2008-05-15 | 2014-12-23 | Celgene Corp | PHARMACEUTICAL COMPOSITION, AND, USE OF 5-AZACYTIDINE |
EP2321302B1 (en) * | 2008-08-01 | 2014-10-29 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
CA2733591C (en) * | 2008-08-08 | 2016-06-28 | Scinopharm Taiwan Ltd. | Process for making 5-azacytosine nucleosides and their derivatives |
EP2424845A4 (en) * | 2009-04-27 | 2014-03-05 | Reddys Lab Ltd Dr | Preparation of decitabine |
US20110042247A1 (en) * | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
JP2014503597A (en) | 2011-01-31 | 2014-02-13 | セルジーン コーポレイション | Pharmaceutical composition of cytidine analogue and method of use thereof |
BR112013025167A2 (en) | 2011-03-31 | 2019-09-24 | Celgene Int Sarl | process for preparing 5-azacitidine, or a salt, solvate, hydrate, or polymorph thereof, 5-azacitidine, 5-azacitidine salt, or a salt, solvate, hydrate, or polymorph |
WO2013022872A1 (en) | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
AU2012312308B2 (en) | 2011-09-23 | 2015-11-19 | Celgene Corporation | Romidepsin and 5-azacitidine for use in treating lymphoma |
WO2013049093A1 (en) | 2011-09-26 | 2013-04-04 | Celgene Corporation | Combination therapy for chemoresistant cancers |
KR101987861B1 (en) | 2011-11-03 | 2019-06-11 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Administration of nedd-8 activating enzyme inhibitor and hypomethylating agent |
WO2013080221A2 (en) * | 2011-12-01 | 2013-06-06 | Hetero Research Foundation | Process for alvimopan |
US9669048B2 (en) * | 2012-10-25 | 2017-06-06 | Fresenius Kabi Oncology Limited | Stable pharmaceutical composition of 5-aza-2′-deoxycitidine |
US9765108B2 (en) | 2012-11-19 | 2017-09-19 | Shilpa Medicare Limited | Formulation of 5-azacytidine |
WO2014076616A2 (en) * | 2012-11-19 | 2014-05-22 | Shilpa Medicare Limited | Formulations of 5-azacytidine |
WO2014160698A1 (en) | 2013-03-26 | 2014-10-02 | Celgene Corporation | SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
CN103450303A (en) * | 2013-09-04 | 2013-12-18 | 重庆泰濠制药有限公司 | Azacitidine crystal form A and azacitidine crystal form B as well as preparation method thereof |
PL3182996T3 (en) | 2014-08-22 | 2023-04-17 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
US20160095925A1 (en) * | 2014-10-01 | 2016-04-07 | Cadila Healthcare Limited | Stable formulation of azacitidine or salts thereof and their process for preparation |
BR122024000250A2 (en) | 2015-10-15 | 2024-02-27 | Les Laboratoires Servier | USE OF A MUTANT ISOCITRATE 1 (IDH1) DEHYDROGENASE INHIBITOR AND A DNA DEMETHYLATING AGENT |
US10695352B2 (en) | 2015-10-15 | 2020-06-30 | Celgene Corporation | Combination therapy for treating malignancies |
EP3527226A4 (en) * | 2016-10-17 | 2020-06-17 | Daiichi Sankyo Company, Limited | Combination therapy method using mdm2 inhibitor and dna methyltransferase inhibitor |
CN109988207B (en) * | 2017-12-29 | 2022-01-04 | 江苏豪森药业集团有限公司 | Preparation method of azacitidine crystal form |
CN110642901A (en) * | 2019-11-11 | 2020-01-03 | 扬子江药业集团有限公司 | Azacitidine methanolate, preparation method thereof, pharmaceutical composition and application |
WO2022251663A2 (en) * | 2021-05-27 | 2022-12-01 | Emory University | Novel universal anti-rna virus agents |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3350388A (en) | 1963-12-22 | 1967-10-31 | Ceskoslovenska Akademie Ved | Process for the manufacture of 1-glycosyl-5-azacytosines |
DE1922702A1 (en) | 1968-05-08 | 1969-11-20 | Ceskoslovenska Akademie Ved | Process for the preparation of 1-glycosyl-5-azacytosines |
GB1227692A (en) | 1968-11-12 | 1971-04-07 | ||
DE2012888A1 (en) | 1970-03-14 | 1971-09-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 5-azapyrimidine nucleosides |
FR2123632A6 (en) | 1971-01-26 | 1972-09-15 | Ceskoslovenska Akademie Ved | Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine |
US3891623A (en) | 1971-05-04 | 1975-06-24 | Schering Ag | Process for preparing cytidines |
US4082911A (en) | 1975-02-24 | 1978-04-04 | Schering Aktiengesellschaft | Process for the preparation of nucleosides |
US4209613A (en) | 1977-12-20 | 1980-06-24 | Schering Aktiengesellschaft | Process for the preparation of nucleosides |
US5700640A (en) | 1994-09-16 | 1997-12-23 | Basf Aktiengesellschaft | Inducers of gamma globin gene expression and screening assays therefor |
US5985864A (en) | 1996-06-07 | 1999-11-16 | Eisai Co., Ltd. | Polymorphs of donepezil hydrochloride and process for production |
US6642206B2 (en) | 1996-10-16 | 2003-11-04 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
US6723728B2 (en) | 2001-03-01 | 2004-04-20 | Gilead Sciences, Inc. | Polymorphic and other crystalline forms cis-FTC |
US6753426B2 (en) | 1999-07-09 | 2004-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polymorph and process for preparing same |
US20040162263A1 (en) | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
US20040186065A1 (en) | 2003-03-17 | 2004-09-23 | Dumitru Ionescu | Forms of 5-azacytidine |
US20050075508A1 (en) | 2000-09-07 | 2005-04-07 | Masafumi Fukae | Method for crystallization of hydroxycarboxylic acids |
US6943249B2 (en) * | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US7084268B1 (en) | 1999-06-03 | 2006-08-01 | Eisai Co., Ltd. | Carbapenem compound crystals and interjection preparations |
US7132552B2 (en) | 2003-02-03 | 2006-11-07 | Teva Pharmaceutical Industries, Ltd. | Process for producing levetiracetam |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
US20070190022A1 (en) | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
US20080057086A1 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
WO2008088779A2 (en) | 2007-01-11 | 2008-07-24 | Ivax Pharmaceuticals S.R.O. | Solid state forms of 5-azacytidine and processes for preparation thereof |
US20080182806A1 (en) | 2007-01-25 | 2008-07-31 | Nevada Cancer Institute | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents |
WO2009016617A2 (en) | 2007-08-02 | 2009-02-05 | Chemagis Ltd. | Stable highly pure azacitidine and preparation methods therefor |
US20090286752A1 (en) | 2008-05-15 | 2009-11-19 | Etter Jeffrey B | Oral formulations of cytidine analogs and methods of use thereof |
US7642247B2 (en) | 2002-09-24 | 2010-01-05 | Koronis Pharmaceuticals, Incorporated | 1,3,5-triazines for treatment of viral diseases |
US20100036112A1 (en) | 2008-08-08 | 2010-02-11 | Scinopharm Taiwan Ltd. | Process for Making 5-Azacytosine Nucleosides and Their Derivatives |
US20100035354A1 (en) | 2008-08-06 | 2010-02-11 | Ettore Bigatti | Process for preparing azacytidine intermediate |
US20100210833A1 (en) | 2007-10-10 | 2010-08-19 | Oliver Jungmann | Method of producing nucleosides |
US20100311683A1 (en) | 2007-11-01 | 2010-12-09 | Beach C L | Cytidine analogs for treatment of myelodysplastic syndromes |
WO2011014541A1 (en) | 2009-07-30 | 2011-02-03 | Eagle Pharmaceuticals, Inc. | Stable formulations of azacitidine |
US20110042247A1 (en) | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
US20110201800A1 (en) | 2008-08-01 | 2011-08-18 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
US20110245485A1 (en) | 2010-03-30 | 2011-10-06 | Chemi Spa | Process for the synthesis of azacitidine and decitabine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5539209A (en) | 1994-10-17 | 1996-07-23 | Trojan Technologies Inc. | Method of cleaning fouling materials from a radiation module |
JPH1053576A (en) * | 1996-06-07 | 1998-02-24 | Eisai Co Ltd | Polymorphic crystal of donepezil hydrochloride and its production |
CA2396079A1 (en) | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
US6877855B2 (en) | 2003-07-08 | 2005-04-12 | Dave Ng | Spectacles with peripheral lens support |
-
2003
- 2003-03-17 US US10/390,530 patent/US6943249B2/en not_active Expired - Lifetime
-
2004
- 2004-03-16 ES ES10151392.7T patent/ES2575535T3/en not_active Expired - Lifetime
- 2004-03-16 SI SI200432065T patent/SI1608634T1/en unknown
- 2004-03-16 PT PT101513927T patent/PT2181988E/en unknown
- 2004-03-16 PT PT47210786T patent/PT1608634E/en unknown
- 2004-03-16 ES ES04721078T patent/ES2425474T3/en not_active Expired - Lifetime
- 2004-03-16 EP EP10151392.7A patent/EP2181988B1/en not_active Revoked
- 2004-03-16 EP EP10178178A patent/EP2266965A1/en not_active Withdrawn
- 2004-03-16 JP JP2006507211A patent/JP4792550B2/en not_active Expired - Lifetime
- 2004-03-16 WO PCT/US2004/007896 patent/WO2004082822A2/en active Application Filing
- 2004-03-16 DK DK04721078.6T patent/DK1608634T3/en active
- 2004-03-16 BR BRPI0408506-0A patent/BRPI0408506A/en not_active IP Right Cessation
- 2004-03-16 HU HUE10151392A patent/HUE028268T2/en unknown
- 2004-03-16 PL PL10151392.7T patent/PL2181988T3/en unknown
- 2004-03-16 AU AU2004222274A patent/AU2004222274B2/en not_active Expired
- 2004-03-16 DK DK10151392.7T patent/DK2181988T3/en active
- 2004-03-16 SI SI200432323A patent/SI2181988T1/en unknown
- 2004-03-16 PL PL04721078T patent/PL1608634T3/en unknown
- 2004-03-16 EP EP04721078.6A patent/EP1608634B1/en not_active Expired - Lifetime
- 2004-03-16 CA CA002518973A patent/CA2518973A1/en not_active Withdrawn
- 2004-03-16 MX MXPA05009969A patent/MXPA05009969A/en active IP Right Grant
-
2005
- 2005-08-05 US US11/198,550 patent/US7700770B2/en not_active Expired - Lifetime
- 2005-09-16 EC EC2005006023A patent/ECSP056023A/en unknown
-
2010
- 2010-03-22 US US12/729,116 patent/US8211862B2/en not_active Expired - Lifetime
- 2010-11-03 AU AU2010241198A patent/AU2010241198B2/en not_active Expired
-
2012
- 2012-06-05 US US13/489,307 patent/US8481715B2/en not_active Expired - Lifetime
-
2013
- 2013-06-07 US US13/913,163 patent/US8975392B2/en not_active Expired - Lifetime
- 2013-08-14 CY CY20131100700T patent/CY1114213T1/en unknown
-
2016
- 2016-05-31 CY CY20161100474T patent/CY1117639T1/en unknown
Patent Citations (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3350388A (en) | 1963-12-22 | 1967-10-31 | Ceskoslovenska Akademie Ved | Process for the manufacture of 1-glycosyl-5-azacytosines |
DE1922702A1 (en) | 1968-05-08 | 1969-11-20 | Ceskoslovenska Akademie Ved | Process for the preparation of 1-glycosyl-5-azacytosines |
GB1227691A (en) | 1968-05-08 | 1971-04-07 | ||
GB1227692A (en) | 1968-11-12 | 1971-04-07 | ||
DE2012888A1 (en) | 1970-03-14 | 1971-09-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 5-azapyrimidine nucleosides |
US3817980A (en) | 1970-03-14 | 1974-06-18 | Schering Ag | 5-azapyrimidine nucleosides |
FR2123632A6 (en) | 1971-01-26 | 1972-09-15 | Ceskoslovenska Akademie Ved | Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine |
US3891623A (en) | 1971-05-04 | 1975-06-24 | Schering Ag | Process for preparing cytidines |
US4082911A (en) | 1975-02-24 | 1978-04-04 | Schering Aktiengesellschaft | Process for the preparation of nucleosides |
US4209613A (en) | 1977-12-20 | 1980-06-24 | Schering Aktiengesellschaft | Process for the preparation of nucleosides |
US5700640A (en) | 1994-09-16 | 1997-12-23 | Basf Aktiengesellschaft | Inducers of gamma globin gene expression and screening assays therefor |
US5985864A (en) | 1996-06-07 | 1999-11-16 | Eisai Co., Ltd. | Polymorphs of donepezil hydrochloride and process for production |
US6642206B2 (en) | 1996-10-16 | 2003-11-04 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
US7084268B1 (en) | 1999-06-03 | 2006-08-01 | Eisai Co., Ltd. | Carbapenem compound crystals and interjection preparations |
US6753426B2 (en) | 1999-07-09 | 2004-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polymorph and process for preparing same |
US20050075508A1 (en) | 2000-09-07 | 2005-04-07 | Masafumi Fukae | Method for crystallization of hydroxycarboxylic acids |
US6723728B2 (en) | 2001-03-01 | 2004-04-20 | Gilead Sciences, Inc. | Polymorphic and other crystalline forms cis-FTC |
US7642247B2 (en) | 2002-09-24 | 2010-01-05 | Koronis Pharmaceuticals, Incorporated | 1,3,5-triazines for treatment of viral diseases |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20040162263A1 (en) | 2002-10-31 | 2004-08-19 | Supergen, Inc., A Delaware Corporation | Pharmaceutical formulations targeting specific regions of the gastrointesinal tract |
US7132552B2 (en) | 2003-02-03 | 2006-11-07 | Teva Pharmaceutical Industries, Ltd. | Process for producing levetiracetam |
US20110092694A1 (en) | 2003-03-17 | 2011-04-21 | Pharmion Llc | Synthesis of 5-azacytidine |
US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
US7772199B2 (en) | 2003-03-17 | 2010-08-10 | Celgene Corporation | Forms of 5-azacytidine |
US8211862B2 (en) | 2003-03-17 | 2012-07-03 | Pharmion Llc | Pharmaceutical compositions comprising crystal forms of 5-azacytidine |
US20100292180A1 (en) | 2003-03-17 | 2010-11-18 | Dumitru Ionescu | Pharmaceutical Compositions Comprising Crystal Forms of 5-Azacytidine |
US20120245342A1 (en) | 2003-03-17 | 2012-09-27 | Pharmion Llc | Methods for isolating crystalline form i of 5-azacytidine |
US7078518B2 (en) | 2003-03-17 | 2006-07-18 | Pharmion Corporation | Forms of 5-Azacytidine |
US6943249B2 (en) * | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
WO2004082619A2 (en) | 2003-03-17 | 2004-09-30 | Pharmion Corporation | Forms of 5-azacytidine |
US20130059809A1 (en) | 2003-03-17 | 2013-03-07 | Pharmion Llc | Pharmaceutical compositions comprising forms of 5-azacytidine |
US8481715B2 (en) * | 2003-03-17 | 2013-07-09 | Pharmion Llc | Methods for isolating crystalline form I of 5-azacytidine |
US20130059810A1 (en) | 2003-03-17 | 2013-03-07 | Pharmion Llc | Pharmaceutical compositions comprising forms of 5-azacytidine |
US20120029181A1 (en) | 2003-03-17 | 2012-02-02 | Pharmion Llc | Synthesis of 5-azacytidine |
US8058424B2 (en) | 2003-03-17 | 2011-11-15 | Pharmion Llc | Synthesis of 5-azacytidine |
US7700770B2 (en) * | 2003-03-17 | 2010-04-20 | Celgene Corporation | Methods for isolating crystalline form I of 5-azacytidine |
US7858774B2 (en) | 2003-03-17 | 2010-12-28 | Pharmion Llc | Synthesis of 5-azacytidine |
US20040186065A1 (en) | 2003-03-17 | 2004-09-23 | Dumitru Ionescu | Forms of 5-azacytidine |
US20100298253A1 (en) | 2003-03-17 | 2010-11-25 | Dumitru Ionescu | Pharmaceutical Compositions Comprising Forms of 5-Azacytidine |
US20070190022A1 (en) | 2003-08-29 | 2007-08-16 | Bacopoulos Nicholas G | Combination methods of treating cancer |
US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
US20100062992A1 (en) | 2004-09-17 | 2010-03-11 | Supergen, Inc. | Salts of 5-Azacytidine |
US20060063735A1 (en) | 2004-09-17 | 2006-03-23 | Supergen, Inc. | Salts of 5-azacytidine |
WO2006034154A2 (en) | 2004-09-17 | 2006-03-30 | Supergen, Inc. | Salts of 5-azacytidine |
US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
US20060074046A1 (en) | 2004-09-27 | 2006-04-06 | Sanjeev Redkar | Oral administration of decitabine salt |
US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20080057086A1 (en) | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
US7759481B2 (en) | 2007-01-11 | 2010-07-20 | Ivax Corporation | Solid state forms of 5-azacytidine and processes for preparation thereof |
WO2008088779A2 (en) | 2007-01-11 | 2008-07-24 | Ivax Pharmaceuticals S.R.O. | Solid state forms of 5-azacytidine and processes for preparation thereof |
US20080182806A1 (en) | 2007-01-25 | 2008-07-31 | Nevada Cancer Institute | Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents |
WO2009016617A2 (en) | 2007-08-02 | 2009-02-05 | Chemagis Ltd. | Stable highly pure azacitidine and preparation methods therefor |
US20100210833A1 (en) | 2007-10-10 | 2010-08-19 | Oliver Jungmann | Method of producing nucleosides |
US20100311683A1 (en) | 2007-11-01 | 2010-12-09 | Beach C L | Cytidine analogs for treatment of myelodysplastic syndromes |
US20090286752A1 (en) | 2008-05-15 | 2009-11-19 | Etter Jeffrey B | Oral formulations of cytidine analogs and methods of use thereof |
US20110201800A1 (en) | 2008-08-01 | 2011-08-18 | Dr. Reddy's Laboratories Ltd. | Azacitidine process and polymorphs |
US20100035354A1 (en) | 2008-08-06 | 2010-02-11 | Ettore Bigatti | Process for preparing azacytidine intermediate |
US20100036112A1 (en) | 2008-08-08 | 2010-02-11 | Scinopharm Taiwan Ltd. | Process for Making 5-Azacytosine Nucleosides and Their Derivatives |
US20110042247A1 (en) | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
WO2011014541A1 (en) | 2009-07-30 | 2011-02-03 | Eagle Pharmaceuticals, Inc. | Stable formulations of azacitidine |
US20110245485A1 (en) | 2010-03-30 | 2011-10-06 | Chemi Spa | Process for the synthesis of azacitidine and decitabine |
Non-Patent Citations (75)
Title |
---|
Ault, Techniques and Experiments for Organic Chemistry, 6th ed., University Science Books, 59-60 (1998). |
Beers et al. (eds.), Chapter 142, Section 11, in The Merck Manual of Diagnosis and Therapy, 18th Edition, pp. 1114-1116 (2006). |
Beisler et al., "Chemistry of Antitumor Triazine Nucleosides. An Improved Synthesis of Dihydro-5-Azacytidine," J. Carbohydrates Nucleosides Nucleotides, 4(5): 281-99 (1977). |
Beisler et al., "Synthesis and Antitumor Activity of Dihydro-5-azacytidine, a Hydrolytically Stable Analogue of 5-Azacytidine," J. Med. Chem., 20(6): 806-12 (1977). |
Beisler, "Isolation, Characterization, and Properties of a Labile Hydrolysis Product of the Antitumor Nucleoside, 5-Azacytidine," J. Med. Chem., 21(2): 204-08 (1978). |
Bergy et al., "Microbiological Production of 5-Azacytidine II. Isolation and Chemical Structure," Antimicrobial Agents and Chemotherapy. 625-30 (1966). |
Bond et al., "Controlling Crystal Architecture in Molecular Solids: the Supramolecular Approach," in Supramolecular Organization and Materials Design, Jones & Rao eds., Cambridge University Press, Chapter 12, pp. 391-443 (2002). |
Braga et al., "Making Crystals From Crystals: a Green Route to Crystal Engineering and Polymorphism," Chemical Communications, 3635-45 (2005). |
Brittain, "Polymorphism: Pharmaceutical Aspects," in Encyclopedia of Pharmaceutical Technology, 2nd Edition, vol. 3, Swarbrick & Boylan eds., pp. 2239-2249 (2002). |
Byrn et al., "Drugs as Molecular Solids," in Solid-State Chemistry of Drugs, 2nd Edition, pp. 3-43 (1999). |
Cabri et al., "Polymorphisms and Patent, Market, and Legal Battles: Cefdinir Case Study," Organic Process Research & Development, 11: 64-72 (2007). |
Chan, K.K. et al.. "5-Azacytidine Hydrolysis Kinetics Measured by High-Pressure Liquid Chromatography and 13C-NMR Spectroscopy," J. Pharm. Sci., 68(7): 807-12 (1979). |
Chen et al., "Highly Efficient Regioselective Synthesis of 5′-O-lauroyl-5-azacytidine Catalyzed by Candida antarctica Lipase B," Appl. Biochem. Biotechnol., 151: 21-28 (2008). |
Chen et al., "Highly Efficient Regioselective Synthesis of 5'-O-lauroyl-5-azacytidine Catalyzed by Candida antarctica Lipase B," Appl. Biochem. Biotechnol., 151: 21-28 (2008). |
Communication Pursuant to Rule 114(2) EPC, enclosing a third party observation, issued by the EPO on Jan. 31, 2013 for European Application No. 10151392.7. |
Day et al., "An Assessment of Lattice Energy Minimization for the Prediction of Molecular Organic Crystal Structures," Crystal Growth & Design, 4(6): 1327-40 (2004). |
Dean, Analytical Chemistry Handbook, pp. 10.23-10.26 (1995). |
Dintaman et al., "Inhibition of P-Glycoprotein by D-alpha-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)," Pharmaceutical Research, 16(10): 1550-1556 (1999). |
Dintaman et al., "Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)," Pharmaceutical Research, 16(10): 1550-1556 (1999). |
Dover et al., "5-Azacytidine Increases HbF Production and Reduces Anemia in Sickle Cell Disease: Dose-Response Analysis of Subcutaneous and Oral Dosage Regimens," Blood, 66(3): 527-532 (1985). |
Final Office Action dated Mar. 6, 2012 in U.S. Appl. No. 12/787,214. |
Garcia-Manero et al., "A Pilot Pharmacokinetic Study of Oral Azacitidine," Leukemia, 22: 1680-84 (2008). |
Garcia-Manero et al., "Phase 1 Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia," J. Clin. Oncol., 29(18): 2521-27 (2011). |
Gaubert et al., "Unnatural Enantiomers of 5-Azacytidine Analogues: Synthesis and Enzymatic Properties," Nucleosides, Nucleotides & Nucleic Acids, 20(4-7): 837-40 (2001). |
Giron, "Investigations of Polymorphism and Pseudo-Polymorphism Pharmaceuticals by Combined Thermoanalytical Techniques," Journal of Thermal Analysis and Calorimetry, 64: 37-60 (2001). |
Giron, "Thermal Analysis and Calorimetric Methods in the Characterisation of Polymorphs and Solvates," Thermochimica Acta, 248: 1-59 (1995). |
Guillory, "Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids," in Polymorphism in Pharmaceutical Solids, pp. 183-226 (1999). |
Gut et al., "Aza Analogs of Pyrimidine and Purine Bases of Nucleic Acids," in Advances in Heterocyclic Chemistry, vol. 1, Katritzky ed., pp. 189-251 (1963). |
Hanka et al., "Microbiological Production of 5-Azacytidine I. Production and Biological Activity," Antimicrobial Agents and Chemotherapy, 619-24 (1966). |
Hilfiker et al., in Polymorphism in the Pharmaceutical Industry, pp. 1-19,287-308 (2006). |
Jain et al., "Polymorphism in Pharmacy," Indian Drugs, 23(6): 315-29 (1986). |
John Beisler, Journal of Medicinal Chemistry, 21(2), (1978), p. 204-8. * |
Jones et al., "Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement," MRS Bulletin, 31: 875-79 (2006). |
Khankari et al.. "Pharmaceutical Hydrates." Thermochimica Acta, 248: 61-79 (1995). |
Knapman, "Polymorphic Predictions: Understanding the Nature of Crystalline Compounds Can Be Critical in Drug Development and Manufacture," Modern Drug Discovery, 53-57 (2000). |
Kornblith et al., "Impact of Azacytidine on the Quality of Life of Patients with Myelodysplastic Syndrome Treated in a Randomized Phase III Trial: A Cancer and Leukemia Group B Study," J. Clin Oncol., 20(10): 2441-52 (2002). |
Kritz et al., "Pilot Study of 5-Azacytidine (5-AZA) and Carboplatin (CBDCA) in Patients with Relapsed/Refractory Leukemia," American Journal of Hematology, 51(2): 117-21 (1996). |
Landgrebe, Organic Laboratory, 4th Edition, pp. 111-112 (1993). |
Lin et al., "High Performance Liquid Chromatographic Analysis of Chemical Stability of 5-Aza-2′-deoxycytidine," J. Pharm. Sci., 70(11): 1228-32 (1981). |
Lin et al., "High Performance Liquid Chromatographic Analysis of Chemical Stability of 5-Aza-2'-deoxycytidine," J. Pharm. Sci., 70(11): 1228-32 (1981). |
Morissette et al., "Elucidation of Crystal Form Diversity of the HIV Protease Inhibitor Ritonavir by High-Throughput Crystallization," Proc. Natl. Acad. Sci., 100(5): 2180-84 (2003). |
New Experimental Chemistry Seminar, Basic Operation I, Japan Chemical Society, 3rd Print, pp. 318-327 (1978). |
Niedballa et al., "A General Synthesis of N-Glycosides. V. Synthesis of 5-Azacytidines," J. Org. Chem., 39(25): 3672-74 (1974). |
Non-Final Office Action dated Dec. 3, 2012 in U.S. Appl. No. 13/489,307. |
Non-Final Office Action dated Sep. 23, 2011 in U.S. Appl. No. 12/787,214. |
Notari et al., "Kinetics and Mechanisms of Degradation of the Antileukemic Agent 5-Azacytidine in Aqueous Solutions," J. Pharm. Sci., 64(7), 1148-57 (1975). |
Notice of Allowance dated Mar. 14, 2013 in U.S. Appl. No. 13/489,307. |
Notice of Allowance dated May 4, 2012 in U.S. Appl. No. 12/729,116. |
Notice of Allowance dated Sep. 20, 2011 in U.S. Appl. No. 12/729,116. |
Office Action dated Aug. 1, 2011 in U.S. Appl. No. 12/466,213. |
O'Neil et al. (eds.), The Merck Index, 14th Edition, p. 150 (2006). |
O'Neil et al. (eds.). The Merck Index, 13th Edition, p. 154-55 (2001). |
Opposition Brief dated Sep. 3, 2007 in Chile Application No. 2267-2005 (with English translation). |
Piskala et al., "4-Amino-l-Beta-D-Ribofuranosyl-Triazin-2(1H)-one (5-azacytidine)," Nucleic Acid Chem., 1: 435-41 (1978). |
Piskala et al., "Direct Synthesis of 5-Azapyrimidine Ribonucleosides," Nucleic Acids Research, Special Pub. No. 1: s17-20 (1975). |
Piskala et al., "Nucleic Acids Components and Their Analogues. LI. Synthesis of 1-Glycosyl Derivatives of 5-Azauracil and 5-Azacytosine," Collect. Czech. Chem. Commun., 29: 2060-76 (1964). |
Rothrock, Contractor Report ARLCD-CR-80052 (1981), DMSO Recrystallization of HMX and RDX. * |
Seddon, "Pseudopolymorph: A Polemic," Crystal Growth & Design, 4(6): 1087 (2004). |
Silverman et al., "Randomized Controlled Trial of Azacitidine in Patients with the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B," J. Clin. Oncol., 20(10): 2429-40 (2002). |
Skikne et al.. "A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)," Journal of Clinical Oncology (May 20, 2008 Supplement), 2008 ASCO Annual Meeting Proceedings (Meeting Date: May 30-Jun. 3, 2008), Part I, 2008, 26(15S), poster # 7091 (2008). |
Stavchansky et al., "Bioavailability in Tablet Technology," in Pharmaceutical Dosage Forms, Tablets, 2nd Edition, Revised and Expanded, vol. 2 of 3, Lieberman et al. eds., pp. 462-472 (1990). |
Stoltz et al., "Development of an Oral Dosage Form of Azacitidine: Overcoming Challenges in Chemistry, Formulation, and Bioavailability," Blood, 48th ASH Annual Meeting (Meeting Date: Dec. 9-12, 2006), 108, poster # 4850 (2006). |
Vippagunta et al., "Crystalline Solids," Advanced Drug Delivery Reviews, 48: 3-26 (2001). |
Vogler et al., "5-Azacytidine (NSC 102816): A New Drug for the Treatment of Myeloblastic Leukemia," Blood, 48(3): 331-37 (1976). |
Vorbruggen et al., "A New Simplified Nucleoside Synthesis," Chem. Ber., 114: 1279-86 (1981). |
Vorbruggen et al., "Nucleoside Synthesis with Trimethylsilyl Triflate and Perchlorate as Catalysts," Chem. Ber., 114: 1234-55 (1981). |
Vorbruggen et al., in Organic Reactions, vol. 55, 100 (L.A. Paquette ed., John Wiley & Sons, New York, 2000). |
Ward et al., "An Oral Dosage Formulation of Azacitidine: A Pilot Pharmacokinetic Study," Journal of Clinical Oncology (Jun. 20, 2007 Supplement), 2007 ASCO Annual Meeting Proceedings (Meeting Date: Jun. 1-5, 2007), Part I, 25(18S), poster # 7084 (2007). |
Wikipedia Recrystallization (1989). * |
Winkley et al., "Direct Glycosylation of 1,3,5-Triazinones. A New Approach to the Synthesis of the Nucleoside Antibiotic 5-Azacytidine (4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2-one) and Related Derivatives," J. Org. Chem., 35(2): 491-95 (1970). |
Winkley et al., "Direct Glycosylation of 1,3,5-Triazinones. A New Approach to the Synthesis of the Nucleoside Antibiotic 5-Azacytidine (4-Amino-1-β-D-ribofuranosyl-1,3,5-triazin-2-one) and Related Derivatives," J. Org. Chem., 35(2): 491-95 (1970). |
Wittenburg et al.. "A New Synthesis of Nucleosides," Zeitschrift fur Chemie, 4: 303-04 (1964) (with English translation). |
Zaitseva et al., "Convergent Syntheses and Cytostatic Properties of 2-Chloro-2′-Deoxy-2′-Fluoroadenosine and its N7-Isomer," Bioorg. & Med. Chem. Lett., 5(24): 2999-3002 (1995). |
Zaitseva et al., "Convergent Syntheses and Cytostatic Properties of 2-Chloro-2'-Deoxy-2'-Fluoroadenosine and its N7-Isomer," Bioorg. & Med. Chem. Lett., 5(24): 2999-3002 (1995). |
Ziemba et al., "Development of Oral Demethylating Agents for the Treatment of Myelodysplastic Syndromes," American Association of Cancer Research, 100th Annual Meeting, Apr. 18-22, Abstract #3369 (2009). |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8975392B2 (en) | Methods for isolating crystalline form I of 5-azacytidine | |
US7078518B2 (en) | Forms of 5-Azacytidine | |
AU2013200662B2 (en) | Methods for isolating crystalline Form I of 5-azacytidine | |
AU2012209018B2 (en) | Methods for isolating crystalline Form I of 5-azacytidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: PHARMION LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHARMION CORPORATION;REEL/FRAME:034716/0447 Effective date: 20080307 Owner name: PHARMION CORPORATION, COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SILVEY, GARY L.;REEL/FRAME:034716/0226 Effective date: 20030714 Owner name: PHARMION LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CELGENE INTERNATIONAL SARL;REEL/FRAME:034716/0555 Effective date: 20100630 Owner name: CELGENE INTERNATIONAL SARL, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASH STEVENS, INC.;REEL/FRAME:034716/0489 Effective date: 20100604 Owner name: ASH STEVENS, INC., MICHIGAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:IONESCU, DUMITRU;BLUMBERGS, PETER;SIGNING DATES FROM 20030715 TO 20030717;REEL/FRAME:034716/0344 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |